This Phase 3 clinical trial enrolled 582 adults, 65 years and older.  

On January 12, 2022, Pfizer Inc. (NYSE:PFE) today announced positive top-line results.

Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the Pfizer-BioNTech COVID-19 Vaccine (n=190) or with placebo (n=191). Responses to a booster dose of the Pfizer-BioNTech COVID-19 Vaccine were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of the Pfizer-BioNTech COVID-19 Vaccine generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.

The study included adults who received their second dose of the COVID vaccine at least six months prior to entering the coadministration study.

Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.

At this time no coadministration data are included in the PREVNAR 20 or Pfizer-BioNTech COVID-19 Vaccine prescribing information.